AMRN AMARIN CORP PLC\UK
Pharmaceutical Preparations · Nasdaq · SEC CIK 897448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.3%
TTM net income YoY77.8%
TTM EPS YoY81.0%
Revenue 3-yr CAGR-18.3%
Net income 3-yr CAGR—
Margins
Gross margin40.9%
Operating margin-18.2%
Net margin-10.9%
FCF margin—
EBITDA margin—
Returns
ROE-4.2%
ROA-3.0%
ROIC (approx.)-8.1%
Asset turnover0.27x
Leverage & solvency
Liabilities / assets29.9%
Debt / equity0.00x
Current ratio3.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $213.65M | $228.61M | $306.91M | $369.19M | $583.19M |
| Cost of revenue | — | — | — | — | $121.33M |
| Gross profit | $120.87M | $81.38M | $165.54M | $242.48M | $461.86M |
| R&D expense | $19.81M | $20.87M | $22.22M | $30.41M | $29.31M |
| SG&A expense | $115.00M | $152.31M | $199.94M | $304.42M | $408.33M |
| Operating income | -$50.17M | -$91.80M | -$67.59M | -$105.87M | $10.50M |
| Interest expense | $7,000 | $7,000 | $8,000 | $15,000 | $129,000 |
| Pretax income | -$36.05M | -$77.20M | -$53.67M | -$103.81M | $11.29M |
| Income tax | $2.75M | $4.98M | $5.44M | $2.00M | $3.56M |
| Net income | -$38.80M | -$82.18M | -$59.11M | -$105.80M | $7.73M |
| EBITDA | — | -$91.70M | -$67.39M | -$105.27M | $11.10M |
| EPS (basic) | -0.09 | -0.20 | -0.15 | -0.26 | 0.02 |
| EPS (diluted) | -0.09 | -0.20 | -0.15 | -0.26 | 0.02 |
| Weighted avg. shares (diluted) | 414.98M | 410.94M | 407.65M | 401.15M | 402.48M |
| Balance sheet | |||||
| Cash & equivalents | $134.66M | $121.04M | $199.25M | $217.67M | $219.45M |
| Short-term investments | $167.93M | $173.18M | $121.41M | $91.69M | $234.67M |
| Receivables | $126.83M | $122.28M | $133.56M | $130.99M | $163.65M |
| Inventory | $195.91M | $166.05M | $258.62M | $228.73M | $234.68M |
| Current assets | $649.88M | $595.40M | $724.98M | $689.10M | $878.73M |
| PP&E, net | $12,000 | $16,000 | $114,000 | $874,000 | $1.43M |
| Intangibles | $13.37M | $16.39M | $19.30M | $21.78M | $23.55M |
| Total assets | $670.77M | $685.35M | $831.68M | $886.18M | $1.07B |
| Current liabilities | $194.46M | $179.95M | $259.28M | $259.48M | $370.68M |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $211.49M | $199.17M | $279.59M | $290.85M | $400.97M |
| Shareholders' equity | $459.28M | $486.18M | $552.10M | $595.33M | $667.10M |
| Shares outstanding | 416.21M | 411.58M | 408.82M | 408.82M | 396.60M |
| Cash flow statement | |||||
| Operating cash flow | $6.73M | -$31.02M | $6.88M | -$180.09M | -$66.54M |
| Investing cash flow | $8.83M | -$45.98M | -$25.52M | $175.29M | $104.10M |
| Financing cash flow | -$2.03M | -$1.44M | $230,000 | -$379,000 | -$5.07M |
| Depreciation & amortization | — | $100,000 | $200,000 | $600,000 | $600,000 |
| Stock-based compensation | $13.94M | $17.70M | $15.65M | $26.21M | $36.94M |
Free plan shows the latest 5 periods; Pro shows all 20 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.